Rao Madduri Ravin 4

What Happened Rao Madduri Ravin, a director of Autolus Therapeutics plc, was granted two restricted stock unit (RSU) awards on June 29, 2026 — 31,667 RSUs and 47,500 RSUs, for a total of 79,167 RSUs. The awards are reported at an acquisition price of $0.00 and are filed as derivative awards (code A). Each RSU represents a contingent right to one American Depositary Share (ADS), and each ADS is convertible into one ordinary share (see footnote F1).

Key Details

• Transaction date: 2026-06-29; Filing date: 2026-07-01 (filed promptly after the transaction).
• Grants: 31,667 RSUs and 47,500 RSUs (total 79,167 RSUs); reported price $0.00; reported as derivative awards.
• Shares owned after transaction: Not specified in the provided filing.
• Footnotes: F1 — each RSU = contingent right to 1 ADS (convertible to 1 ordinary share); F2 — RSUs vest in one installment on June 29, 2027; F3 — separate share options (if any) vest in 12 monthly installments starting July 29, 2026.
• No 10b5-1 plan, tax withholding sale, or immediate disposition of vested shares was reported in the provided data.

Context These RSUs are compensation/retention awards that create a future entitlement to ADSs if vesting conditions are met; they are not an open‑market purchase or sale. The reported acquisition price of $0.00 is standard for grants — the economic value to the holder will depend on Autolus’s ADS/share price at vesting.